Concordia Healthcare Corp. to host second quarter 2014 results conference call

TORONTO, July 31, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF) today announced it will release its second quarter 2014 financial results after market close on Wednesday, August 13, 2014. The Company will subsequently hold a conference call on Thursday, August 14, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update.

This call is being webcast and can be accessed from the Concordia website at www.concordiarx.com. An archived replay of the webcast will be available for one year.

About Concordia

Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs and medical devices for the diabetic population. The company's legacy pharmaceutical business consists of an ADHD-treatment drug, Kapvay® (clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin® in the United States.

Concordia operates out of facilities in Oakville, Ontario, Lenexa, Kansas (near Kansas City, Missouri), Bannockburn, (near Chicago), Illinois and Bridgetown, Barbados.

SOURCE Concordia Healthcare Corp.